Protagonist Therapeutics (NASDAQ:PTGX) Stock Rating Raised to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a buy rating to a strong-buy rating in a research report report published on Saturday,Wall Street Zen reports.

Other research analysts have also issued reports about the stock. Weiss Ratings lowered shares of Protagonist Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Wolfe Research reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, August 31st. Wedbush lifted their price target on Protagonist Therapeutics from $118.00 to $173.00 and gave the stock an “outperform” rating in a report on Monday, August 10th. BMO Capital Markets lifted their price target on Protagonist Therapeutics from $178.00 to $190.00 and gave the stock an “outperform” rating in a report on Tuesday, September 1st. Finally, Citigroup boosted their price target on Protagonist Therapeutics from $175.00 to $182.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $166.67.

Check Out Our Latest Report on PTGX

Protagonist Therapeutics Trading Down 2.4%

Shares of PTGX opened at $132.04 on Friday. The company has a market cap of $8.54 billion, a price-to-earnings ratio of 27.97 and a beta of 1.21. Protagonist Therapeutics has a 1-year low of $76.70 and a 1-year high of $160.81. The company’s fifty day simple moving average is $141.52 and its 200 day simple moving average is $117.83.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $3.07 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. The firm had revenue of $274.41 million during the quarter, compared to analysts’ expectations of $238.49 million. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 48.62%. As a group, research analysts forecast that Protagonist Therapeutics will post 4.59 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $149.11, for a total value of $9,805,622.71. Following the completion of the sale, the chief executive officer directly owned 523,478 shares in the company, valued at $78,055,804.58. The trade was a 11.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the company’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the transaction, the chief financial officer directly owned 59,003 shares in the company, valued at approximately $8,365,445.34. This represents a 49.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 283,629 shares of company stock worth $41,443,786. 5.19% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. TFB Advisors LLC lifted its stake in shares of Protagonist Therapeutics by 3.0% in the third quarter. TFB Advisors LLC now owns 5,394 shares of the company’s stock worth $760,000 after acquiring an additional 159 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in Protagonist Therapeutics by 7.8% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,760 shares of the company’s stock valued at $291,000 after purchasing an additional 200 shares during the period. GAMMA Investing LLC increased its position in Protagonist Therapeutics by 7.2% during the 2nd quarter. GAMMA Investing LLC now owns 3,109 shares of the company’s stock valued at $381,000 after purchasing an additional 208 shares during the period. Choreo LLC increased its position in Protagonist Therapeutics by 9.3% during the 3rd quarter. Choreo LLC now owns 2,533 shares of the company’s stock valued at $357,000 after purchasing an additional 216 shares during the period. Finally, Keating Financial Advisory Services Inc. bought a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.

The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V.

See Also

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.